UNSPSC 51434934: Hydralazine/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434934 Hydralazine/hydrochlorothiazide is a Commodity code used by state and local procurement bodies to classify individual pharmaceutical products. Recent state and local solicitations under this code and related pharmaceutical purchasing show that jurisdictions actually buy advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through formal competitive bidding and cooperative purchasing mechanisms. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all recently solicited pharmaceutical supply contracts. Issuing bodies include city procurement departments acting on behalf of emergency services, state health agencies, and interstate cooperative purchasing consortiums that aggregate demand across member jurisdictions. These entities typically require vendors to supply specific medication line items with firm pricing, compliance certifications, and expedited delivery windows.

Activity spreads across Florida, Texas, Minnesota, and Oregon through MMCAP's multistate framework. The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with response due April 8, 2026, seeking four medication line items (Labetalol, Epinephrine, Adenosine, and Diltiazem) with a $40,000 estimated contract value, a Small Local Business Enterprise sheltered-market 5 percent bid discount, and one-year term with two optional one-year renewals plus three unilateral 30-day extensions. The Minnesota Department of Administration's MMCAP consortium issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to provide NDC-coded products through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative fee compliance, EDI capability, and format compliance. The Texas HHS Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription program capabilities, indicating early-stage procurement development without formal competitive parameters or award values.